Pharmaceuticals, Corporate Crime and Public Health

Pharmaceuticals, Corporate Crime and Public Health

Graham Dukes, John Braithwaite and J. P. Moloney

The pharmaceutical industry exists to serve the community, but over the years it has engaged massively in corporate crime, with the public footing the bill. This readable study by experts in medicine, law, criminology and public health documents the problems, ranging from false advertising and counterfeiting to corruption waste and overpricing, with unacceptable pressures on doctors, politicians, patients and the media. Uniquely, the book goes on to present a realistic and worldwide solution for the future, with positive policies encouraging honest dealing as well as partial privatization of enforcement and greater emphasis on creative research to develop the medicines that society needs most.

Chapter 2: Safe, unsafe and improper manufacturing practices

Graham Dukes, John Braithwaite and J. P. Moloney

Subjects: law - academic, biotechnology and pharmaceutical law, health law, social policy and sociology, health policy and economics


Many of the world’s medicines are manufactured in precisely the sort of stainless steel and glass factories that are the showpieces of modern industry, fitted out with sophisticated equipment and staffed by white-coated experts. Procedures for Good Manufacturing Practice (GMP) are laid down in fine detail, with approval and inspection by the health authorities, and laboratories are to hand for checking every stage of production. In almost every respect, the standards applicable to drug manufacturing are accessible, absolute and applicable across the board. In the making of pharmaceuticals, just as in the building of aircraft, there is after all no room for error: the misplacement of a single screw when constructing a plane may lead to the death of hundreds of passengers; with medicines, which can be active in microgram quantities, the toxic dose of the active substance may be only very slightly higher than the dose used in treatment, and the slightest slip in formulation may have tragic consequences for numerous users. In one respect the pharmaceutical situation creates even more stringent demands; while an aircraft will be checked and rechecked by any conscientious operator before each flight, a medicine, once packaged in the factory, is unlikely to be examined again before it is opened and consumed by the patient; at that stage even a serious quality defect is likely to go unrecognized until disaster supervenes.

You are not authenticated to view the full text of this chapter or article.

Elgaronline requires a subscription or purchase to access the full text of books or journals. Please login through your library system or with your personal username and password on the homepage.

Non-subscribers can freely search the site, view abstracts/ extracts and download selected front matter and introductory chapters for personal use.

Your library may not have purchased all subject areas. If you are authenticated and think you should have access to this title, please contact your librarian.

Further information